Relapsed/Refractory Multiple Myeloma MedDRA version: 12.1 Level: LLT Classification code 10028228 Term: Multiple myeloma
Conditions
Interventions
Product Name: APLIDIN (plitidepsin)
Product Code: Not applicable
Pharmaceutical Form: Powder and solvent for solution for infusion
INN or Proposed INN: plitidepsin
CAS Number: 137219-37-5
Concentratio
Sponsors
Pharma Mar, S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age = 18 years. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2. 3. Life expectancy = 3 months. 4. Patients previously diagnosed with multiple myeloma based on IMWG diagnostic criteria. 5. Patients must have relapsed or relapsed and refractory multiple myeloma (MM)after at least three but not more than six prior therapeutic regimens for MM, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen. 6. Patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available), unless unable to tolerate either of them. 7. Patients must have measurable disease defined as: a) For secretory MM: any quantifiable serum monoclonal protein value and, where applicable, urine light-chain excretion = 200 mg/24 hours. b) For oligo- or non-secretory MM: presence of soft tissue (not bone) plasmacytomas, as determined by clinical examination or applicable radiographs [i.e., magnetic resonance imaging (MRI), computed tomography (CT)-scan], and/or by the presence of abnormal serum free light chains (sFLC): involved FLC level = 10 mg/dl provided the serum FLC ratio is abnormal. 8. At least two-week washout period since the end of last therapy (six weeks if previous nitrosoureas-containing regimen), given recovery to grade = 1 from any non-hematological related adverse event (AE) derived from previous treatment (excluding alopecia). 9. Adequate bone marrow (BM), renal, hepatic, and metabolic function (assessed = 7 days before inclusion in the study): a) Absolute neutrophil count (ANC) = 1.0 x 109/l (= 0.5 x 109/l if due to extensive and documented BM involvement by = 50% of plasma cells in BM biopsy). - Screening of ANC should be independent of granulocyte- and granulocyte/macrophage-colony stimulating factor (G-CSF and GM-CSF) support for at least one week and of pegylated G-CSF for at least two weeks. b) Platelet count = 50 x 109/l (= 25 x 109/l if due to extensive and documented BM disease involvement). c) Hemoglobin = 8.5 g/dl. - Patients may receive red blood cells (RBC) and/or erythropoietin (EPO), and/or platelets transfusions in accordance with institutional guidelines. d) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x the upper limit of normal (ULN). e) Direct bilirubin = 1.0 x ULN. f) Calculated creatinine clearance (CrCl) = 30 ml/minute (by means of Cockcroft and Gault´s formula). g) Creatine phosphokinase (CPK) = 2.5 x ULN. h) Albumin = 2.5 g/dl. 10. Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) above the lower limit of normal (LLN). 11. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment. 12. Voluntarily signed and dated written informed consent prior to any specific study procedure. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Concomitant diseases/conditions: a) History or presence of angina, myocardial infarction, clinically relevant valvular heart disease, cardiac amyloidosis or congestive heart failure within the last 12 months. b) Symptomatic arrhythmia (excluding anemia-related sinusal tachycardia grade = 2) or any arrhythmia requiring ongoing treatment, and/or prolonged QT-QTc grade = 2. c) Active uncontrolled infection or recent history of acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose. d) Morphological or cytological features of myelodysplasia and/or post-chemotherapy aplasia on BM assessment. e) Myopathy > grade 2 or any clinical situation that causes significant and persistent elevation of CPK (>2.5 x ULN in two different determinations performed one week apart). f) Known human immunodeficiency virus (HIV) infection (HIV testing is not required unless infection is clinically suspected). g) Known active hepatitis B or C virus (HBV or HCV) infection. h) Limitation of the patient’s ability to comply with the treatment or follow-up requirements. i) Any other major illness that, in the Investigator’s judgment, will substantially increase the risk associated with the patient’s participation in this study. j) Peripheral neuropathy > grade 2. 2. Women who are pregnant or breast feeding. 3. Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM, within two weeks prior to Cycle 1 Day 1. Concurrent corticosteroids are allowed, provided they are administered at an equivalent prednisone dose of = 10 mg daily, as premedication for blood products only. 4. Known history of peptic ulcer and/or major upper gastrointestinal bleeding episode occurring during last year before study entry and/or related to prior steroid-based therapy. 5. Relevant history of mood-disturbances changes associated with previous steroid-based therapy. 6. Disease-related symptomatic hypercalcemia despite optimal medical therapy. 7. Known hypersensitivity to any involved study drug or any of its formulation components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM).;Secondary Objective: To evaluate tumor response according to the International Myeloma Working Group (IMWG) criteria. To assess duration of response (DR) and overall survival (OS). To assess efficacy in patients who undergo crossover from dexamethasone alone to plitidepsin and dexamethasone combination. To characterize and compare the safety profile on both arms in this population. To characterize the pharmacokinetics (PK) and pharmacokinetic /pharmacodynamic (PK/PD) relationship.;Primary end point(s): PFS, according to IRC assessment, as per intention-to-treat (ITT) analysis. | — |
Countries
Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
Outcome results
None listed